Orphan drugs

孤儿药 斯科普斯 医学 家庭医学 罕见病 业务 谈判 政治学 梅德林 疾病 法学 生物信息学 病理 生物
作者
Francesca Cainelli,Sandro Vento
出处
期刊:The Lancet [Elsevier BV]
卷期号:393 (10181): 1594-1594
标识
DOI:10.1016/s0140-6736(19)30016-9
摘要

Lucio Luzzatto and colleagues1Luzzatto L Hyry HI Schieppati A et al.Outrageous prices of orphan drugs: a call for collaboration.Lancet. 2018; 392: 791-794Summary Full Text Full Text PDF PubMed Scopus (99) Google Scholar (Sept 1, 2018, p 791) have called for collaboration from EU member states on negotiation of orphan drug prices to take advantage of the fact that with 500 million inhabitants, the EU is the largest customer for any new drug. Low-income and middle-income countries (LMICs), with more than 6 billion inhabitants and 360–480 million patients with rare diseases,2Auvin S Irwin J Abi-Aad P Battersby A The problem of rarity: estimation of prevalence in rare disease.Value Health. 2018; 21: 501-507Summary Full Text Full Text PDF PubMed Scopus (38) Google Scholar are in need of orphan drugs and should join forces in this area. Rare diseases cannot continue to be neglected in developing countries, and international collaboration among these countries is vital to change the situation. Screening programmes should be introduced for more diseases, and educational programmes for doctors (especially paediatricians and general practitioners) and nurses should be implemented; these would raise the number of diagnoses and reduce misdiagnoses. Most importantly, more patients with rare diseases for which drugs are available should be treated. Legislations, regulations, and policies for orphan drugs should be drafted and implemented (a review article3Gammie T Lu CY Babar ZU-D Access to orphan drugs: a comprehensive review of legislations, regulations and policies in 35 countries.PLoS One. 2015; 10: e0140002Crossref PubMed Scopus (145) Google Scholar failed to identify any pertinent legislation in Latin American and African countries). Patient organisations should be created in LMICs and should play a prominent role in increasing awareness and urging governments to provide treatment for rare diseases, particularly for children. Provision of antiretrovirals to HIV-infected patients in LMICs was considered impossible on economic grounds 20 years ago, and became a reality in 2010; a joint effort from patient organisations and governments could make the provision of orphan drugs to patients in need in the same countries a reality. We declare no competing interests. Outrageous prices of orphan drugs: a call for collaborationFew instances of a single act of legislation have shifted industrial policy in the pharmaceutical industry like the Orphan Drugs Act did when it was signed in the USA in 1983. The Act was written to facilitate the development of drugs for rare diseases and health conditions,1 and the incentives provided by the Act, such as 7 year exclusivity, tax credits of up to 50% of research and development costs, and access to research and development grants, resulted in the US Food and Drug Administration2 (FDA) approving 575 drugs and biological products for rare diseases between 1983 and 2017—a real success. Full-Text PDF Orphan drugsThe Viewpoint by Luzzatto and colleagues1 on drug pricing addresses a very crucial issue because an increasing number of orphan drugs have been marketed in the past decade, and genetic treatments costing more than €300 000 are being made available. Among the determinants of drug pricing reported in the Viewpoint,1 benefit to the patient is the main factor that is typically examined in cost-effectiveness analyses; disease-specific factors are already recognised to influence drug prices because an inverse association exists between treatment cost and disease prevalence. Full-Text PDF Orphan drugsLuzzatto and colleagues1 give three recommendations for pricing orphan drugs. We will focus on the first recommendation (European price negotiation) and on the first part of the second (cost-based pricing). Full-Text PDF Orphan drugs – Authors' replyWe agree with Francesca Cainelli and Sandro Vento that patients with orphan diseases, regardless of location, ought to receive the best treatment available. We share their appeal on behalf of low-income and middle-income countries for access to orphan drugs. Full-Text PDF
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
bwx完成签到,获得积分10
1秒前
CodeCraft应助jm采纳,获得10
2秒前
3秒前
苹果完成签到,获得积分20
3秒前
yy发布了新的文献求助10
3秒前
maizhan完成签到,获得积分10
5秒前
默认用户名完成签到,获得积分10
6秒前
7秒前
leei完成签到,获得积分10
8秒前
meng123发布了新的文献求助10
8秒前
小马甲应助c123采纳,获得10
9秒前
莎莎士比亚完成签到,获得积分10
11秒前
LOST完成签到 ,获得积分10
11秒前
12秒前
袁凯文发布了新的文献求助10
12秒前
共享精神应助老菜鸟321采纳,获得10
12秒前
WUWEI发布了新的文献求助10
13秒前
xiaoW完成签到,获得积分10
13秒前
15秒前
牛太虚完成签到,获得积分10
15秒前
SciGPT应助科多兽骑士采纳,获得10
15秒前
17秒前
gjm完成签到,获得积分10
17秒前
SciGPT应助zj采纳,获得10
18秒前
Ava应助阿湫采纳,获得10
18秒前
meng123完成签到,获得积分20
19秒前
x5kyi完成签到,获得积分10
20秒前
爆米花应助肖遥采纳,获得10
21秒前
Xx完成签到,获得积分10
21秒前
21秒前
24秒前
烟里戏完成签到 ,获得积分10
26秒前
shuangfeng1853完成签到 ,获得积分10
26秒前
林子青发布了新的文献求助10
26秒前
27秒前
aa完成签到,获得积分10
27秒前
CXC完成签到,获得积分10
27秒前
29秒前
Zzz发布了新的文献求助10
29秒前
上官若男应助袁凯文采纳,获得10
30秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038524
求助须知:如何正确求助?哪些是违规求助? 3576221
关于积分的说明 11374737
捐赠科研通 3305912
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892688
科研通“疑难数据库(出版商)”最低求助积分说明 815048